SCHEMBL15701723

SCHEMBL15701723

CCCCN(c1ccc2c(c1)OCCO2)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
HPGD P15428 4/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27009977 0.82 HPGD (0.48) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL14149516 0.80 ADRA2A (0.46) L3MBTL1HPGDTP53RAB9AADRA2A
SCHEMBL21600799 0.76 ADRA2A (0.50) L3MBTL1HPGDRAB9AADRA2AADRA2B
SCHEMBL5293408 0.75 L3MBTL1 (0.46) L3MBTL1HPGDRAB9AHSD17B10ALDH1A1
SCHEMBL15701706 0.72 TAAR1 (0.49) L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL27650176 0.71 HPGD (0.51) HPGDRAB9AALDH1A1MAPTMEN1
SCHEMBL8122254 0.71 SIGMAR1 (0.45) HPGDTP53RAB9AADRA2AADRA2B
SCHEMBL15701713 0.70 SMN1; SMN2 (0.40) L3MBTL1HPGDRAB9AALDH1A1MAPT
SCHEMBL15701712 0.70 LMNA (0.40) ALDH1A1LMNAMEN1KMT2A
SCHEMBL6872368 0.69 ESR1 (0.45) TP53ADRA2AADRA2BADRA2CHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 L3MBTL1 2432/4885HPGD 1804/4885TP53 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.